Stock Traders Purchase High Volume of Agios Pharmaceuticals Call Options (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 8,407 call options on the stock. This represents an increase of 582% compared to the average daily volume of 1,233 call options.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AGIO. HC Wainwright reissued a “buy” rating and set a $56.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Thursday, November 13th. Bank of America cut their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Tuesday, July 22nd. Finally, Scotiabank cut their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research note on Monday, July 28th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $57.25.

Agios Pharmaceuticals Stock Down 49.6%

AGIO traded down $22.55 during trading hours on Wednesday, reaching $22.95. 9,514,397 shares of the company’s stock traded hands, compared to its average volume of 732,422. The firm has a market capitalization of $1.34 billion, a PE ratio of -3.25 and a beta of 0.89. The firm has a 50-day moving average price of $40.64 and a 200 day moving average price of $37.01. Agios Pharmaceuticals has a 52-week low of $22.35 and a 52-week high of $62.45.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm had revenue of $12.90 million during the quarter, compared to analysts’ expectations of $10.49 million. During the same period in the previous year, the business posted $16.22 EPS. The business’s revenue was up 43.3% compared to the same quarter last year. Equities analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Activity

In related news, insider Theodore James Jr. Washburn sold 8,546 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $36.87, for a total transaction of $315,091.02. Following the completion of the transaction, the insider owned 868 shares of the company’s stock, valued at $32,003.16. This trade represents a 90.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Cecilia Jones sold 3,651 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the transaction, the chief financial officer owned 33,870 shares in the company, valued at approximately $1,245,399.90. The trade was a 9.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,099 shares of company stock worth $620,092 over the last 90 days. 4.93% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Bellevue Group AG boosted its stake in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after purchasing an additional 124,586 shares in the last quarter. Erste Asset Management GmbH lifted its stake in Agios Pharmaceuticals by 18.8% in the third quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company’s stock valued at $108,578,000 after buying an additional 438,411 shares during the period. Wellington Management Group LLP raised its position in Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares during the last quarter. Commodore Capital LP increased its stake in shares of Agios Pharmaceuticals by 0.6% during the 3rd quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock worth $93,859,000 after purchasing an additional 13,287 shares during the last quarter. Finally, TCG Crossover Management LLC boosted its stake in Agios Pharmaceuticals by 105.2% in the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after purchasing an additional 733,038 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.